MA45420A - Traitements combinés avec seribantumab - Google Patents

Traitements combinés avec seribantumab

Info

Publication number
MA45420A
MA45420A MA045420A MA45420A MA45420A MA 45420 A MA45420 A MA 45420A MA 045420 A MA045420 A MA 045420A MA 45420 A MA45420 A MA 45420A MA 45420 A MA45420 A MA 45420A
Authority
MA
Morocco
Prior art keywords
seribantumab
combined treatments
treatments
combined
Prior art date
Application number
MA045420A
Other languages
English (en)
French (fr)
Inventor
Bambang Adiwijaya
Akos Czibere
Gavin Macbeath
Rachel C Nering
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MA45420A publication Critical patent/MA45420A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA045420A 2015-04-17 2016-04-15 Traitements combinés avec seribantumab MA45420A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562149271P 2015-04-17 2015-04-17

Publications (1)

Publication Number Publication Date
MA45420A true MA45420A (fr) 2019-05-01

Family

ID=55854801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045420A MA45420A (fr) 2015-04-17 2016-04-15 Traitements combinés avec seribantumab

Country Status (13)

Country Link
US (1) US20160303232A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283068A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018513155A (cg-RX-API-DMAC7.html)
KR (1) KR20170137886A (cg-RX-API-DMAC7.html)
CN (1) CN107750165A (cg-RX-API-DMAC7.html)
AU (1) AU2016248329A1 (cg-RX-API-DMAC7.html)
CA (1) CA2983008A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792294A1 (cg-RX-API-DMAC7.html)
HK (2) HK1248539A1 (cg-RX-API-DMAC7.html)
IL (1) IL255092A0 (cg-RX-API-DMAC7.html)
MA (1) MA45420A (cg-RX-API-DMAC7.html)
SG (1) SG11201708491PA (cg-RX-API-DMAC7.html)
WO (1) WO2016168730A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161009A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment
AU2018211985B2 (en) * 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
CN112654363A (zh) 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
KR20230109668A (ko) 2020-11-16 2023-07-20 서로젠 오퍼레이팅, 인크. 간-특이적 Wnt 신호 증강 분자 및 그의 용도
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP2711434B1 (en) 2005-06-20 2016-09-14 Advanced Cell Diagnostics, Inc. Multiplex detection of nucleic acids
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
US9011863B2 (en) * 2010-07-09 2015-04-21 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
BR112013022882A2 (pt) 2011-03-11 2016-12-20 Merrimack Pharmaceuticals Inc uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
JP2014527035A (ja) * 2011-06-30 2014-10-09 メリマック ファーマシューティカルズ インコーポレーティッド 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ＥｒｂＢ３抗体
AU2012294326A1 (en) 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
AU2013201584A1 (en) 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
WO2015048793A2 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Nucleic acid biomarker and use thereof
EP3087394A2 (en) * 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Also Published As

Publication number Publication date
EP3283068A1 (en) 2018-02-21
HK1250626A1 (zh) 2019-01-11
KR20170137886A (ko) 2017-12-13
JP2018513155A (ja) 2018-05-24
IL255092A0 (en) 2017-12-31
CN107750165A (zh) 2018-03-02
US20160303232A1 (en) 2016-10-20
HK1248539A1 (zh) 2018-10-19
CA2983008A1 (en) 2016-10-20
EA201792294A1 (ru) 2018-03-30
AU2016248329A1 (en) 2017-11-09
WO2016168730A1 (en) 2016-10-20
SG11201708491PA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
PL3345230T3 (pl) Podwójny perowskit
EP3374114A4 (en) WORKBENCH
DK3244762T3 (da) Træningstøj
MA45129A (fr) Traitements du cancer
EP3365027A4 (en) HU-SPECIFIC INTERFERING ACTIVE SUBSTANCES
EP3297102A4 (en) Connector
MA45420A (fr) Traitements combinés avec seribantumab
KR101490087B9 (ko) 장신구 조립체
FI20165867A7 (fi) Valoherkiste
DK3393478T3 (da) Kombinationsterapi
DK3154689T3 (da) Komplekser
EP3362091A4 (en) COMBINATION THERAPY
EP3354988A4 (en) STOVE
ME03312B (me) Vorтiokseтin piroglutamat
EP3299263A4 (en) TRACTOR
EP3305185A4 (en) SPHYGMOMANOMETER
EP3384016A4 (en) MANIPULATED PHAGEMIDES
DK3154945T3 (da) Komplekser
FI20145032A7 (fi) Nasta
EP3321153A4 (en) TRACTOR
EP3496725A4 (en) THERAPIES FOR REMYELINISATION
DK3436447T3 (da) Isoquinolinyl-triazolon-komplekser
KR101574461B9 (ko) 장신구 조립체
DK3222767T3 (da) Vaskefremgangsmåde
FI10942U1 (fi) Koriste-elementti